Latest HER2/neu Stories
Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D., director of medical oncology at the San Raffaele Cancer Center in Milano, Italy, presented results from AVEREL, a randomized, phase 3 trial, at the 2011...
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo. Researchers conducted an international phase 3, double-blind, randomized trial, known as CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab), in which they randomly assigned 808 patients to receive trastuzumab and...
WORCESTER, Mass. and TORONTO, Dec. 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The AE37 vaccine is being developed by its wholly-owned subsidiary,...
BROOMFIELD, Colo., Dec. 7, 2011 /PRNewswire/ -- Results from the VeriStrat retrospective analysis of the Phase III trial, EGF30008, were presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The EGF30008 study compared Femara(®) plus placebo to Femara plus Tykerb(®) in 1st line, hormone receptor positive, advanced breast cancer patients. The study included both Her2 positive and Her2 negative patients. Results showed that the VeriStrat test was able to...
Newly published research explores the role of 14-3-3σ in tumor suppression New research out of McGill University's Goodman Cancer Research Centre provides compelling new evidence that a gene known as 14-3-3σ plays a critical role in halting breast cancer initiation and progression. The study, led by the Dept. of Biochemistry's William J. Muller, will be published online today in the journal Cancer Discovery. The discovery of this new target points to novel therapies that eventually...
SAN DIEGO, Nov. 16, 2011 /PRNewswire/ -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) To our Shareholders: Earlier this year, we introduced and began marketing the Aethlon ADAPT(TM) system, a technology platform that intersects the medical device and drug world to establish a new class of therapeutics that allow for the...
SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Biocept, Inc. today reported that its scientists and academic collaborators will present three posters at the 34th annual San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, TX December 6-10, 2011. The poster presentations describe data generated on Biocept's proprietary OncoCEE(TM) (Oncology Cell Enrichment and Extraction) platform, which enables efficient CTC capture and detection, as well as biomarker analysis on the captured...
Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience. If validated, the use of anaplastic lymphoma kinase (ALK) inhibitors may be a new treatment approach for patients with this lethal form of breast cancer. These data were presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer...
CAMBRIDGE, Mass., Nov. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that they will present seven posters on six novel pipeline programs at the 2011 American Association for Cancer Research (AACR)/National Cancer Institute (NCI)/European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics taking place November 12-16, 2011, in San Francisco, California. (Logo:...
Current testing protocols for HER2 amplification may exclude thousands of patients who actually have HER2 gene amplification, delaying or preventing them from receiving potentially life-saving treatment. A new laboratory testing protocol can more accurately identify an important group of breast cancer patients who are most likely to benefit from a “targeted therapy†shown to dramatically improve survival. This recent discovery by PhenoPath Laboratories could improve the...
